PMID- 11819733
OWN - NLM
STAT- MEDLINE
DCOM- 20020507
LR  - 20231104
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 7
IP  - 1
DP  - 2001 Feb
TI  - Relationship between phenotypes of cell-function differentiation and 
      pathobiological behavior of gastric carcinomas.
PG  - 53-9
AB  - AIM: To reveal the correlation between the functional differentiation phenotypes 
      of gastric carcinoma cells and the invasion and metastasis by a new way of 
      cell-function classification. METHODS: Surgically resected specimens of 361 
      gastric carcinomas(GC) were investigated with enzyme-, mucin-, and tumor-related 
      marker immunohistochemistry. According to the direction of cell-function 
      differentiation, stomach carcinomas were divided into five functionally 
      differentiated types. RESULTS: (1) Absorptive function differentiation type 
      (AFDT): there were 82 (22.7%) patients including 76 (92.7%) aged 45 years. 
      Sixty-nine (84.1%) cases belonged to the intestinal type. Thirty-eight (46.3%) 
      expressed CD44v6 and 9 (13.6%) of 66 male patients developed liver metastasis. 
      The 5-year survival rate of patients in this group (58.5%) was higher than those 
      with the other types (P<0.01). (2) Mucin secreting function differentiation type 
      (MSFDT): 54 (15%) cases. Fifty-three (98.1%) tumors had penetrated the serosa, 12 
      (22.2%) expressed ER and 22 (40.7%) expressed CD44v6. The postoperative 5-year 
      survival rate was 28.6%. (3) Absorptive and mucin-producing function 
      differentiation type (AMPFDT): there were 180 (49.9%) cases, including 31 (17.2%) 
      aged younger than 45 years. The tumor was more common in women (62, 34.4%,) and 
      expressed more frequently estrogen receptors (ER) (129, 81.7%) than other types 
      (P<0.01). Ovary metastasis was found in 12 (19.4%) out of 62 female subjects. The 
      patients with this type GC had the lowest 5-year survival rate (24.7%) among all 
      types. (4) Specific function differentiation type (SFDT): 13 (3.6%) cases. Nine 
      (69.2%) tumors of this type derived from APUD system, the other 4 (30.7%) were of 
      different histological differentiation. Sixty per cent of the patients survived 
      at least five years. (5) Non-function differentiation type (NFDT): 32 (8.9%) 
      cases. Nineteen (59.4%) cases had lymph node metastases but no one with liver or 
      ovary metastasis. The 5-year survival rate was 28.1%. CONCLUSION: This new 
      cell-function classification of GC is helpful in indicating the characteristics 
      of invasion and metastasis of GC with different cell-function differentiation 
      phenotypes. Further study is needed to disclose the correlation between the 
      cell-functional differentiation phenotypes and the relevant genotypes and the 
      biological behavior of gastric carcinoma.
FAU - Xin, Y
AU  - Xin Y
AD  - The Fourth Laboratory of Cancer Institute, China Medical University, Shenyang 
      110001, Liaoning Province, China.
FAU - Li, X L
AU  - Li XL
FAU - Wang, Y P
AU  - Wang YP
FAU - Zhang, S M
AU  - Zhang SM
FAU - Zheng, H C
AU  - Zheng HC
FAU - Wu, D Y
AU  - Wu DY
FAU - Zhang, Y C
AU  - Zhang YC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD44v6 antigen)
RN  - 0 (Glycoproteins)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Cell Differentiation
MH  - Female
MH  - Glycoproteins/genetics
MH  - Humans
MH  - Hyaluronan Receptors/genetics
MH  - Immunohistochemistry
MH  - Liver Neoplasms/secondary
MH  - Lymphatic Metastasis/genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness/genetics/pathology
MH  - Ovarian Neoplasms/secondary
MH  - Phenotype
MH  - Prognosis
MH  - Receptors, Estrogen/genetics
MH  - Stomach Neoplasms/*classification/genetics/mortality/*secondary
MH  - Survival Rate
PMC - PMC4688701
EDAT- 2002/01/31 10:00
MHDA- 2002/05/08 10:01
PMCR- 2001/02/15
CRDT- 2002/01/31 10:00
PHST- 2002/01/31 10:00 [pubmed]
PHST- 2002/05/08 10:01 [medline]
PHST- 2002/01/31 10:00 [entrez]
PHST- 2001/02/15 00:00 [pmc-release]
AID - 10.3748/wjg.v7.i1.53 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2001 Feb;7(1):53-9. doi: 10.3748/wjg.v7.i1.53.